Select Medical Holdings Corp. Files 8-K on Financials
Ticker: SEM · Form: 8-K · Filed: Jul 12, 2024 · CIK: 1320414
Sentiment: neutral
Topics: financial-condition, results-of-operations
TL;DR
SELECT MEDICAL HOLDINGS CORP filed an 8-K on 7/12/24 detailing financial results.
AI Summary
Select Medical Holdings Corp. filed an 8-K on July 12, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the company's performance. The report was submitted under the Securities Exchange Act of 1934.
Why It Matters
This 8-K filing provides investors with crucial updates on Select Medical Holdings Corp.'s financial performance and operational results, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine filing of financial results and does not indicate any unusual or immediate risks.
Key Players & Entities
- SELECT MEDICAL HOLDINGS CORP (company) — Registrant
- July 12, 2024 (date) — Date of Report
- 4714 Gettysburg Road (address) — Principal executive offices
- Mechanicsburg, PA 17055 (address) — Principal executive offices
- 717-972-1100 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Select Medical Holdings Corp.'s results of operations and financial condition, including financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on July 12, 2024.
Under which act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the principal executive office address for Select Medical Holdings Corp.?
The principal executive office address is 4714 Gettysburg Road, Mechanicsburg, PA 17055.
What is the registrant's telephone number?
The registrant's telephone number is (717) 972-1100.
Filing Stats: 546 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-07-12 16:48:51
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share SEM New York Stock Exchange
Filing Documents
- tm2419380d1_8k.htm (8-K) — 28KB
- tm2419380d1_ex99-1.htm (EX-99.1) — 64KB
- tm2419380d1_ex99-1img001.jpg (GRAPHIC) — 33KB
- tm2419380d1_ex99-1img002.jpg (GRAPHIC) — 16KB
- 0001104659-24-079579.txt ( ) — 338KB
- sem-20240712.xsd (EX-101.SCH) — 3KB
- sem-20240712_lab.xml (EX-101.LAB) — 33KB
- sem-20240712_pre.xml (EX-101.PRE) — 22KB
- tm2419380d1_8k_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On July 12, 2024, Select Medical Holdings Corporation issued a press release announcing an estimate of certain financial results for its wholly-owned subsidiary Concentra Group Holdings Parent, Inc. for the second quarter ended June 30, 2024 (the " Press Release "). A copy of the Press Release and the attached financial schedules are attached as Exhibit 99.1 to this report and incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated July 12, 2024, announcing an estimate of certain financial results for the second quarter ended June 30, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorized. SELECT MEDICAL HOLDINGS CORPORATION Date: July 12, 2024 By: /s/ Michael E. Tarvin Michael E. Tarvin Senior Executive Vice President, General Counsel and Secretary